Interpretability of the Quality Of Life in Hand Eczema Questionnaire (QOLHEQ).

Related Articles

Interpretability of the Quality Of Life in Hand Eczema Questionnaire (QOLHEQ).

J Invest Dermatol. 2019 Oct 10;:

Authors: Oosterhaven JAF, Ofenloch RF, Schuttelaar MLA

Abstract
The Quality Of Life in Hand Eczema Questionnaire (QOLHEQ) is used to measure impairment of health-related quality of life (HRQoL) in hand eczema. Here, we prospectively studied the interpretability of international QOLHEQ scores at three time points: baseline, after 1-3 days (T1) and after 4-12 weeks (T2). Adult patients with hand eczema completed the QOLHEQ and anchor questions for overall assessment of HRQoL impairment. Interpretability of single scores was assessed at baseline by defining severity bands based on agreement with the anchor questions. Smallest detectable change (SDC) was calculated at T1. Minimally important change (MIC) of improvement was calculated at T2 using three methods: mean cut-off, receiver operating curve (ROC) and 95% limit. N=294 adult patients were included (N=160 males, mean age 44.9). The final proposed severity band of overall QOLHEQ single scores (?-coefficient of agreement, 0.431) was: not at all, 0-10; slightly, 11-39; moderately, 40-61; strongly, 62-86; very strongly, ?87. Separate overall severity bands were proposed for males and females, and the four subscales of the QOLHEQ. The SDC in N=166 unchanged patients was 18.6 points. The preferred MIC, obtained with the ROC method was 21.5 points. An overall QOLHEQ score of ? 22 is recommended as cut-off for a minimally important, real change.

PMID: 31606350 [PubMed – as supplied by publisher]

Posted in J Invest Dermatol | Comments Off on Interpretability of the Quality Of Life in Hand Eczema Questionnaire (QOLHEQ).

Patients’ Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial.

Icon for Springer Related Articles

Patients’ Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial.

Drugs Aging. 2019 Sep 13;:

Authors: Edelman M, Jellema P, Hak E, Denig P, Blanker MH

Abstract
OBJECTIVE: The objective of this study was to gain insights into the attitudes of men with lower urinary tract symptoms towards deprescribing alpha-blockers and to assess their willingness to participate in a planned discontinuation trial.
METHODS: This was a cross-sectional questionnaire study. Men aged 30 years and older with lower urinary tract symptoms, who were first prescribed an alpha-blocker in 2015 or 2016, were selected from a population-based prescription database. We recorded lower urinary tract symptom severity (e.g., International Prostate Symptom Score and Overactive Bladder questionnaire) and patient characteristics (e.g., comorbidity and polypharmacy). The linguistically validated Dutch version of the revised Patients’ Attitudes Towards Deprescribing (rPATD) questionnaire was also used, to which we added ten specific questions on attitudes towards the deprescribing of alpha-blockers. Information about a future discontinuation trial on alpha-blockers was then provided and participants were asked to indicate if they would participate. We explored the explanatory factors for the willingness to participate by logistic regression analyses.
RESULTS: Of the 1380 patients in the database, 421 were using an alpha-blocker, and 195 completed the questionnaire. Of these, 16 men were excluded because of indwelling catheter use or unknown indication. The mean age of the 179 participants was 69.4 (standard deviation 9.2) years. Most men were satisfied with their current therapy, but almost all (93%) were willing to stop the medicine at the request of a doctor. Therefore, most men (61%) were willing to participate in the proposed alpha-blocker discontinuation trial. Willingness to stop therapy was affected by patients’ perceptions of the appropriateness of alpha-blocker therapy and concerns about stopping that therapy.
CONCLUSIONS: Although men who use alpha-blockers are generally satisfied with their current therapy, most will participate in a discontinuation trial.

PMID: 31515710 [PubMed – as supplied by publisher]

Posted in Drugs Aging | Comments Off on Patients’ Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial.

Patients’ Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial.

Icon for Springer Related Articles

Patients’ Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial.

Drugs Aging. 2019 Sep 13;:

Authors: Edelman M, Jellema P, Hak E, Denig P, Blanker MH

Abstract
OBJECTIVE: The objective of this study was to gain insights into the attitudes of men with lower urinary tract symptoms towards deprescribing alpha-blockers and to assess their willingness to participate in a planned discontinuation trial.
METHODS: This was a cross-sectional questionnaire study. Men aged 30 years and older with lower urinary tract symptoms, who were first prescribed an alpha-blocker in 2015 or 2016, were selected from a population-based prescription database. We recorded lower urinary tract symptom severity (e.g., International Prostate Symptom Score and Overactive Bladder questionnaire) and patient characteristics (e.g., comorbidity and polypharmacy). The linguistically validated Dutch version of the revised Patients’ Attitudes Towards Deprescribing (rPATD) questionnaire was also used, to which we added ten specific questions on attitudes towards the deprescribing of alpha-blockers. Information about a future discontinuation trial on alpha-blockers was then provided and participants were asked to indicate if they would participate. We explored the explanatory factors for the willingness to participate by logistic regression analyses.
RESULTS: Of the 1380 patients in the database, 421 were using an alpha-blocker, and 195 completed the questionnaire. Of these, 16 men were excluded because of indwelling catheter use or unknown indication. The mean age of the 179 participants was 69.4 (standard deviation 9.2) years. Most men were satisfied with their current therapy, but almost all (93%) were willing to stop the medicine at the request of a doctor. Therefore, most men (61%) were willing to participate in the proposed alpha-blocker discontinuation trial. Willingness to stop therapy was affected by patients’ perceptions of the appropriateness of alpha-blocker therapy and concerns about stopping that therapy.
CONCLUSIONS: Although men who use alpha-blockers are generally satisfied with their current therapy, most will participate in a discontinuation trial.

PMID: 31515710 [PubMed – as supplied by publisher]

Posted in Drugs Aging | Comments Off on Patients’ Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial.

Obituary: Professor Marcel F. Jonkman: 1957-2019.

Icon for Wiley Related Articles

Obituary: Professor Marcel F. Jonkman: 1957-2019.

Br J Dermatol. 2019 Sep;181(3):643-644

Authors: Horváth B, Bolling MC, Steijlen PM

PMID: 31475344 [PubMed – in process]

Posted in Br J Dermatol | Comments Off on Obituary: Professor Marcel F. Jonkman: 1957-2019.

Responsiveness and interpretability of the Hand Eczema Severity Index (HECSI).

Icon for Wiley Related Articles

Responsiveness and interpretability of the Hand Eczema Severity Index (HECSI).

Br J Dermatol. 2019 Jul 01;:

Authors: Oosterhaven JAF, Schuttelaar MLA

Abstract
BACKGROUND: The Hand Eczema Severity Index (HECSI) is used to measure severity of hand eczema. It is unclear what HECSI scores mean and what is the minimally important change (MIC). Furthermore, responsiveness has not been studied.
OBJECTIVES: To study responsiveness and interpretability of the HECSI.
METHODS: Prospective study covering two time points; baseline and after 4-12 weeks. Responsiveness was assessed using a criterion approach with a ? 1 step improvement on the ‘Photographic guide for severity of hand eczema’ as anchor for important improvement. Interpretability of single scores was determined by defining severity bands based on agreement with the anchor. For change scores, smallest detectable change (SDC) was calculated in unchanged patients and MIC was obtained in changed patients using three methods: mean cut-off, receiver operating curve (ROC) and 95%-limit.
RESULTS: N=294 patients participated (N=160 males, mean age 44·9). HECSI scores improved/deteriorated in parallel with the anchor. The area under the ROC curve was 0·86 (95% confidence interval: 0·81-0·91). The final severity band for single scores had a ?-coefficient of agreement of 0·694: clear, 0; almost clear, 1-16; moderate, 17-37; severe, 38-116; very severe, ?117. The SDC in N=93 unchanged patients was 40·3 points. The obtained MIC values were all smaller than the SDC.
CONCLUSIONS: The HECSI has good responsiveness. This study gives meaning to HECSI scores, which can be applied to clinical decision making and the design of clinical trials. We recommend that an improvement of 41 points on the HECSI is regarded as minimally measurable true change. This article is protected by copyright. All rights reserved.

PMID: 31260086 [PubMed – as supplied by publisher]

Posted in Br J Dermatol | Comments Off on Responsiveness and interpretability of the Hand Eczema Severity Index (HECSI).

Cochrane review “Interventions for hand eczema” is published.

Icon for Wiley Related Articles

Cochrane review “Interventions for hand eczema” is published.

Contact Dermatitis. 2019 May 22;:

Authors: Christoffers WA, Coenraads PJ

Abstract
We would like to call your readership’s attention to the recently published Cochrane Review: Interventions for hand eczema.1 We feel that this letter is justified because the Cochrane review is the result of a non-profit collaborative effort and because it addresses a clinical problem encountered by many practicing dermatologists. This article is protected by copyright. All rights reserved.

PMID: 31119748 [PubMed – as supplied by publisher]

Posted in Contact Dermatitis | Comments Off on Cochrane review “Interventions for hand eczema” is published.

Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: a prospective single centre study.

Related Articles

Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: a prospective single centre study.

J Eur Acad Dermatol Venereol. 2019 May 27;:

Authors: Prens LM, Huizinga J, Janse IC, Horváth B

Abstract
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic debilitating skin disease, frequently located in the groin and anogenital area, leading to a substantial impact on quality of life and sexual health in HS patients. Skin-tissue-sparing excision with electrosurgical peeling (STEEP) is a procedure with known low recurrence rates and high patient satisfaction in retrospective series. However, a prospective study to investigate the impact of any major surgery on specific aspects of the quality of life has not yet been performed.
OBJECTIVE: To assess surgical outcomes and the effect of major surgery on the general quality of life, sexual health and activity impairment in HS patients.
MATERIALS AND METHODS: A single centre prospective survey study was conducted among 40 patients undergoing major surgery. Surveys were completed prior to surgery and 2, 6, 12 and 26 weeks after surgery. Besides the objective parameters (time to wound closure and surface of the wound), patient reported outcomes were reported.
RESULTS: Thirty-nine patients with a total of 171 survey responses were included for analysis.. Patients with Hurley stage I or II had a shorter time to wound closure (TTWC) compared to patients with Hurley stage III (p=0.005). TTWC was significantly prolonged in patients treated with biologics (p<0.001). Smoking did not significantly influence TTWC. For patient reported outcomes, DLQI and ASEX scores did not significantly improve during the study period of six months. However, activity and overall work impairment showed considerable improvement after surgery.
CONCLUSION: Time to wound closure is significantly prolonged by, higher Hurley stage and treatment with biologics, contrastingly not by smoking. Major surgery improved the overall work and daily activity impairment. This article is protected by copyright. All rights reserved.

PMID: 31132177 [PubMed – as supplied by publisher]

Posted in J Eur Acad Dermatol Venereol | Comments Off on Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: a prospective single centre study.

Morphine induced cutaneous adverse drug reaction following occupational diacetylmorphine contact dermatitis, a case report.

Related Articles

Morphine induced cutaneous adverse drug reaction following occupational diacetylmorphine contact dermatitis, a case report.

Contact Dermatitis. 2019 May 07;:

Authors: van den Hoed E, Coenraads PJ, Schuttelaar MLA

Abstract
Contact dermatitis from diacetylmorphine (heroin) and from morphine have both been described before.(1-5) In addition, a case of acute generalized exanthematous pustulosis (AGEP) as a reaction to morphine has also previously been described.(6) The present report describes a case who was occupationally sensitized to diacetylmorphine and developed a skin reaction after receiving morphine following surgery. This article is protected by copyright. All rights reserved.

PMID: 31066067 [PubMed – as supplied by publisher]

Posted in Contact Dermatitis | Comments Off on Morphine induced cutaneous adverse drug reaction following occupational diacetylmorphine contact dermatitis, a case report.

Dexamethasone therapy versus surgery for chronic subdural haematoma (DECSA trial): study protocol for a randomised controlled trial.

Icon for BioMed Central Icon for PubMed Central Related Articles

Dexamethasone therapy versus surgery for chronic subdural haematoma (DECSA trial): study protocol for a randomised controlled trial.

Trials. 2018 Oct 20;19(1):575

Authors: Miah IP, Holl DC, Peul WC, Walchenbach R, Kruyt N, de Laat K, Koot RW, Volovici V, Dirven CMF, van Kooten F, Kho KH, den Hertog HM, van der Naalt J, Jacobs B, Groen RJM, Lingsma HF, Dammers R, Jellema K, van der Gaag NA, Dutch Subdural Hematoma Research Group (DSHR)

Abstract
BACKGROUND: Chronic subdural haematoma (CSDH) is a common neurological disease with a rapidly rising incidence due to increasing age and widespread use of anticoagulants. Surgical intervention by burr-hole craniotomy (BHC) is the current standard practice for symptomatic patients, but associated with complications, a recurrence rate of up to 30% and increased mortality. Dexamethasone (DXM) therapy is, therefore, used as a non-surgical alternative but considered to achieve a lower success rate. Furthermore, the benefit of DXM therapy appears much more deliberate than the immediate relief from BHC. Lack of evidence and clinical equipoise among caregivers prompts the need for a head-to-head randomised controlled trial. The objective of this study is to compare the effect of primary DXM therapy versus primary BHC on functional outcome and cost-effectiveness in symptomatic patients with CSDH.
METHODS/DESIGN: This study is a prospective, multicentre, randomised controlled trial (RCT). Consecutive patients with a CSDH with a Markwalder Grading Scale (MGS) grade 1 to 3 will be randomised to treatment with DXM or BHC. The DXM treatment scheme will be 16 mg DXM per day (8 mg twice daily, days 1 to 4) which is then halved every 3 days until a dosage of 0.5 mg a day on day 19 and stopped on day 20. If the treatment response is insufficient (i.e. persistent or progressive symptomatology due to insufficient haematoma resolution), additional surgery can be performed. The primary outcomes are the functional outcome by means of the modified Rankin Scale (mRS) score at 3 months and cost-effectiveness at 12 months. Secondary outcomes are quality of life at 3 and 12 months using the Short Form Health Survey (SF-36) and Quality of Life after Brain Injury Overall Scale (QOLIBRI), haematoma thickness after 2 weeks on follow-up computed tomography (CT), haematoma recurrence during the first 12 months, complications and drug-related adverse events, failure of therapy within 12 months after randomisation and requiring intervention, mortality during the first 3 and 12 months, duration of hospital stay and overall healthcare and productivity costs. To test non-inferiority of DXM therapy compared to BHC, 210 patients in each treatment arm are required (assumed adjusted common odds ratio DXM compared to BHC 1.15, limit for inferiority <?0.9). The aim is to include a total of 420 patients in 3 years with an enrolment rate of 60%.
DISCUSSION: The present study should demonstrate whether treatment with DXM is as effective as BHC on functional outcome, at lower costs.
TRIAL REGISTRATION: EUCTR 2015-001563-39 . Date of registration: 29 March 2015.

PMID: 30342554 [PubMed – indexed for MEDLINE]

Posted in Trials | Comments Off on Dexamethasone therapy versus surgery for chronic subdural haematoma (DECSA trial): study protocol for a randomised controlled trial.

Handekzeme bei niederländischen Imkern – eine Querschnittsuntersuchung.

Icon for Wiley Related Articles

Handekzeme bei niederländischen Imkern – eine Querschnittsuntersuchung.

J Dtsch Dermatol Ges. 2019 Feb;17(2):158-166

Authors: Oosterhaven JAF, Verbist J, Schuttelaar MA

PMID: 30762965 [PubMed – in process]

Posted in J Dtsch Dermatol Ges | Comments Off on Handekzeme bei niederländischen Imkern – eine Querschnittsuntersuchung.

Hand eczema among Dutch beekeepers – a cross-sectional study.

Icon for Wiley Related Articles

Hand eczema among Dutch beekeepers – a cross-sectional study.

J Dtsch Dermatol Ges. 2019 Feb;17(2):158-166

Authors: Oosterhaven JAF, Verbist J, Schuttelaar MA

Abstract
BACKGROUND AND OBJECTIVES: Studies of beekeepers have mostly focused on contact allergy to propolis. The overall prevalence of hand eczema (HE) in beekeepers has not been studied. Our objectives were to gain insight into the prevalence of HE in the Dutch beekeeper population; to define the impact of beekeeping activities on HE and vice versa; and to determine associated factors.
PATIENTS AND METHODS: We used a cross-sectional online survey. Dutch beekeepers answered questions on beekeeping activities, the prevalence and characteristics of HE, including severity, and the impact of the disease on beekeeping.
RESULTS: We analyzed 833 surveys (12 % of Dutch beekeepers). The one-year prevalence of HE was 13.2 %, and the lifetime prevalence was 20.5 %. In 28 patch-tested beekeepers with hand eczema, eight (28.6 %) were allergic to propolis. Atopic dermatitis was the only variable associated with HE: the odds ratio was 4.53 (95 % confidence interval 2.78-7.38). One in three beekeepers reported that HE was caused or worsened by beekeeping, although only 3.8 % reported working less at beekeeping because of HE, and the impact of HE on beekeeping activities (as perceived by beekeepers) is low.
CONCLUSIONS: In this sample of Dutch beekeepers, hand eczema was more prevalent than in the general population, but seems to have had little impact on the beekeeping activities of the majority of beekeepers.

PMID: 30762971 [PubMed – in process]

Posted in J Dtsch Dermatol Ges | Comments Off on Hand eczema among Dutch beekeepers – a cross-sectional study.

[Pruritus in elderly: diagnosis and treatment].

Related Articles

[Pruritus in elderly: diagnosis and treatment].

Ned Tijdschr Geneeskd. 2018 Dec 20;163:

Authors: Leus AJG, Meijer JM, Zuidema SU, Jonkman MF

Abstract
Pruritus is the most common dermatological complaint in elderly people and may have a significant negative influence on quality of life. In elderly, the identification of the underlying cause of pruritus can be difficult, due to the broad differential diagnosis and the frequent occurence of comorbidities and polypharmacy. In daily practice, a classification can be used of ‘pruritus with primary skin lesions’ and ‘pruritus without primary skin lesions’ for a more specific search to the underlying cause. The most common cause of pruritus in elderly is dry skin (xerosis). In primary care pruritis is more often caused by a dermatosis and systemic causes are more rare. Besides treatment directed at the underlying cause, it is recommended in elderly to always treat xerosis with topical emollients. Topical therapy consists of corticosteroids, anaesthetics and anti-inflammatory agents. Systemic treatments include antihistamines, antidepressants and neuroactive medications.

PMID: 30604601 [PubMed – in process]

Posted in Ned Tijdschr Geneeskd | Comments Off on [Pruritus in elderly: diagnosis and treatment].

Response to ‘Serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita: a multicentre analysis’.

Icon for Wiley Related Articles

Response to ‘Serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita: a multicentre analysis’.

Br J Dermatol. 2018 02;178(2):573

Authors: Jonkman MF, Meijer JM, Diercks GFH, Pas HH

PMID: 28977674 [PubMed – indexed for MEDLINE]

Posted in Br J Dermatol | Comments Off on Response to ‘Serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita: a multicentre analysis’.

KLHL24: Beyond Skin Fragility.

Icon for Elsevier Science Related Articles

KLHL24: Beyond Skin Fragility.

J Invest Dermatol. 2019 Jan;139(1):22-24

Authors: Bolling MC, Jonkman MF

Abstract
KLHL24 mutations have recently been associated with epidermolysis bullosa simplex. Initial studies focused on skin fragility. However, the picture of KLHL24 mutations causing extracutaneous human disease is emerging, with dilated cardiomyopathy as a strong association. In addition, neurological disease is suspected as well. Careful clinical follow-up and functional studies of (mutated) KLHL24 in these tissues are needed.

PMID: 30579426 [PubMed – in process]

Posted in J Invest Dermatol | Comments Off on KLHL24: Beyond Skin Fragility.

Immediate hypersensitivity to p-phenylenediamine.

Icon for Wiley Related Articles

Immediate hypersensitivity to p-phenylenediamine.

Contact Dermatitis. 2018 Nov 13;:

Authors: Wilkinson M, Solman L, Coenraads PJ, Goebel C

PMID: 30426523 [PubMed – as supplied by publisher]

Posted in Contact Dermatitis | Comments Off on Immediate hypersensitivity to p-phenylenediamine.